Vascepa

Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in
Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in
Fierce Pharma
Amarin
Vascepa
Flag link:
Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up
Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up
Endpoints
Amarin
Vascepa
FDA
M&A
Flag link:
Diabetes group nods to Vascepa, sending Amarin stock higher
Diabetes group nods to Vascepa, sending Amarin stock higher
Biopharma Dive
ADA
Vascepa
Amarin
diabetes
Flag link:
Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate
Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate
Stat
Amarin
Vascepa
American College of Cardiology
Flag link:
ACC 2019 preview – Bayer hopes for heart failure panache
ACC 2019 preview – Bayer hopes for heart failure panache
EP Vantage
Bayer
heart failure
Amarin
Esperion
ACC
Vascepa
bempedoic acid
Flag link:
Is Amarin Sitting on a Goldmine?
Is Amarin Sitting on a Goldmine?
Motley Fool
Vascepa
Amarin
Flag link:
Pharma's 2019 Prognosis Hinges on These Key Themes
Pharma's 2019 Prognosis Hinges on These Key Themes
Bloomberg
drug pricing
Amarin
Vascepa
IPOs
cancer
Flag link:
2 Biotech Stocks Poised for Big Gains in 2019
2 Biotech Stocks Poised for Big Gains in 2019
Motley Fool
Amarin
Vascepa
Novavax
ResVax
Flag link:
Amarin raises $200M ahead of Vascepa push
Amarin raises $200M ahead of Vascepa push
BioCentury
Amarin
Vascepa
Flag link:
Amarin's Vascepa trial stirs data debate as stock drops 10%
Amarin's Vascepa trial stirs data debate as stock drops 10%
Biopharma Dive
Amarin
Vascepa
Flag link:
Amarin's Fish-Oil-Derived Drug Shows Great Promise — With Big Caveats
Amarin's Fish-Oil-Derived Drug Shows Great Promise — With Big Caveats
Forbes
Amarin
Vascepa
Flag link:
Why Amarin Stock Jumped 28% in October -- and Why a Bigger Move Could Come Soon
Why Amarin Stock Jumped 28% in October -- and Why a Bigger Move Could Come Soon
Motley Fool
Amarin
Vascepa
Flag link:
Experts question Amarin's early touting of Vescepa data ahead of detailed results
Experts question Amarin's early touting of Vescepa data ahead of detailed results
Endpoints
Amarin
Vascepa
heart disease
Flag link:
[video+transcript] How Big Could Amarin's Vascepa Be?
[video+transcript] How Big Could Amarin's Vascepa Be?
Motley Fool
Vascepa
Amarin
Flag link:
3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph
3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph
Yahoo/Motley Fool
Amarin
Vascepa
Amgen
Sanofi
Regeneron
Flag link:
Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study
Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study
Xconomy
Amarin
fish oil
strokes
Vascepa
Flag link:
Why Amarin Corporation Skyrocketed 23.9% in August
Why Amarin Corporation Skyrocketed 23.9% in August
Motley Fool
Amarin
Vascepa
Flag link:
Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week
Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week
Motley Fool
Amarin
CRISPR Therapeutics
Geron
Vascepa
Vertex Pharmaceuticals
CTX001
JNJ
imetelstat
Flag link:
Analysts: Amarin poised for huge gains if Vascepa trial comes back positive
Analysts: Amarin poised for huge gains if Vascepa trial comes back positive
Medical Marketing and Media
Amarin
Vascepa
Flag link:
Amarin's Vascepa goes on TV to lay groundwork for impending CV outcomes data
Amarin's Vascepa goes on TV to lay groundwork for impending CV outcomes data
Fierce Pharma
Amarin
Vascepa
physicians
television ads
Flag link:

Pages